Supernus Pharmaceuticals completes Hart-Scott-Rodino waiting period for Sage Therapeutics acquisition

Supernus Pharmaceuticals announced that the Hart-Scott-Rodino waiting period for its acquisition of Sage Therapeutics has expired. The acquisition is subject to remaining conditions set forth in the Offer to Purchase and will expire at midnight on July 30, 2025. The offer includes a cash price of $8.50 per share and a contingent value right for up to $3.50 per share upon the satisfaction of specified milestones.